摘要
目的:探讨氨磺必利治疗慢性精神分裂症患者的疗效与安全性。方法:将80例慢性精神分裂症患者随机分为氨磺必利组和喹硫平组,每组40例,分别给予患者氨磺必利和喹硫平治疗,疗程12周。于治疗前和治疗2、4、8、12周,采用阳性和阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)评定两组患者的临床疗效;不良反应量表(TESS)、锥体外系副反应量表(RSESE)评定两组患者的不良反应。结果:两组患者的显效率(P>0.05)和有效率(P>0.05)差异无统计学意义;治疗2周,氨磺必利组患者的阳性症状分、阴性症状分、PANSS总分及CGI-SI评分较治疗前显著降低(P<0.05或P<0.001);喹硫平组患者则于治疗4周,PANSS总分及各因子分、CGI-SI评分较治疗前显著降低(P<0.05或P<0.001);治疗4周(P<0.05)、8周(P<0.05)、12周(P<0.05),氨磺必利组患者的PANSS阴性症状分明显优于喹硫平组;两组患者的不良反应较少。结论:氨磺必利治疗慢性精神分裂症患者安全有效。
Objective:To explore efficacy and safety of Amisulpride in treatment of chronic schizophrenia. Methods:80 pa-tients with chronic schizophrenia were randomly assigned to Amisulpride group (n=40) and Quetiapine group (n=40) and treated for 12 weeks. Positive and negative symptom scale ( PANSS) , clinical global impression-severity scale ( CGI-SI) were used to evaluate the efficacy;treatment emergent symptom scale ( TESS) and rating scale for extrapyramidal side effects ( RSESE) were used to meas-ure the side effect before and 2, 4, 8 and 12 weeks after the treatment. Results:There were no significant differences in the obvious effective rate (P>0. 05) and the effective rate (P>0. 05) between the two groups. From the 2nd week, the total scores of PANSS, positive symptom scores, negative symptoms scores and CGI-SI scores of Amisulpride group decreased more remarkably than those be-fore the treatment (P<0. 05 or P<0. 001). From the 4th week, the total and factor scores of PANSS and CGI-SI scores of Quetiapine group decreased more remarkably than those before the treatment (P<0. 05). At the end of the 4th (P<0. 05), 8th (P<0. 05), and 12th (P<0. 05) week, the negative symptoms scores of Amisulpride group were obviously better than those of Quetiapine group. Both groups had fewer adverse reactions. Conclusions:Amisulpride is an effective and safe drug in the treatment of chronic schizophrenia.
出处
《中国民康医学》
2015年第8期9-10,13,共3页
Medical Journal of Chinese People’s Health
